It simultaneously activates three hormone receptors that play central roles in metabolism, appetite regulation, and energy balance: Glucagon-like peptide-1 (GLP-1) receptor Glucose-dependent insulinotropic polypeptide (GIP) receptor Glucagon receptor Previous weight loss medications have targeted one or two of these pathways
Available in various forms, including lyophilized preparations, DSIP Oceania remains a focus of ongoing research, particularly through placebo-controlled studies
JARDIANCE product monograph
For most of the year, the picture looked like this: Of course, the review cycle is long drawn, especially in markets such as Canada, where we have not seen a single generic GLP being approved, including liraglutide, which has not been approved by Health Canada. Siddharth Mittal, CEO & MD, Biocon | Q3 FY26 The export bet has a cleaner economic logic than the domestic one